Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: A meta-analysis of randomised trials

Song, Zhao; Liu, Enqi; Wei, Kai; Lu, Shemin; Chu, Yangyang; Li, Yafeng; Wang, Yanli; Huang, Binke; Chen, Yulong; Yang, Penghui

doi:10.1016/j.antiviral.2010.12.003

Cited by 15 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peginterferon achieved better effects than interferon did in the treatment of hepatitis B in previous studies [23]. Chinese herbs plus interferon have been associated with higher sustained virological response than interferon alone in chronic hepatitis C and B [12][13][14]24]. Chinese herbs have also been reported to improve the adverse effects of peginterferon or interferon in the treatment of chronic hepatitis [14,24].…”

Section: Discussionmentioning

confidence: 95%

“…Chinese herbs plus interferon have been associated with higher sustained virological response than interferon alone in chronic hepatitis C and B [12][13][14]24]. Chinese herbs have also been reported to improve the adverse effects of peginterferon or interferon in the treatment of chronic hepatitis [14,24]. Whether Chinese herbs can better improve virological response than peginterferon alone in HBeAg-positive CHB patients remains unclear.…”

Section: Discussionmentioning

confidence: 99%

“…Adverse reactions to Chinese herbs are rare and negligible when compared to those commonly produced by pharmaceutical drugs [9][10][11][12][13][14]. Interferon plus Chinese herbs is associated with higher sustained virological response than interferon alone in chronic hepatitis C and B [12][13][14]. Whether Chinese herbs can improve virological response compared to that yielded by peginterferon alone in CHB patients remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B

Gao

Cheng

et al. 2016

J Infect Dev Ctries

Self Cite

View full text Add to dashboard Cite

Introduction: Traditional Chinese herbs are widely used for the treatment of chronic hepatitis B (CHB) in China. The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) comparing peginterferon therapies with peginterferon plus Chinese herbal therapies in hepatitis B e antigen (HBeAg)-positive CHB patients. Methodology: The main biomedical databases were searched to identify RCTs that compared the efficiency of peginterferon with peginterferon plus Chinese herbs in CHB patients. Results: The literature search yielded 616 studies, and 8 RCTs (624 patients) matched the selection criteria. Combined therapies of peginterferon plus Chinese herbal therapies were superior to peginterferon therapies alone in achieving the serum HBV DNA clearance rate (64.5% vs. 45.0%), serum HBeAg clearance rate (47.4% vs. 33.5%), and HBeAg seroconversion rates (39.2% vs. 23.1%) at the end of treatment. Combined therapies were more effective than peginterferon alone therapies in the improvement of liver fibrosis related biomarkers, including hyaluronic acid, procollagen type III, type IV collagen, and lamina. Combined therapies also resulted in fewer relapses, fewer adverse events, and more rapid alanine transaminase normalization. Conclusions: The current evidence suggests that peginterferon plus Chinese herbal therapies were associated with higher virological response than peginterferon alone in HBeAg-positive CHB patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B

Gao

Cheng

et al. 2016

J Infect Dev Ctries

Self Cite

View full text Add to dashboard Cite

show abstract

“…In 2011, Zhao et al 61 reported a meta-analysis of RCTs that were carried out between 2001 and 2010 and which had at least 24-week treatment periods, to compare the clinical efficacy and safety of Chinese herbal therapy alone with that in combination with IFN therapy, and IFN therapy alone for the treatment of patients with CHC. They reported that, compared with IFN therapy alone, Chinese herbal therapy alone presented a lower relapse rate as well as a lower ETVR rate.…”

Section: General Overview Of Clinical Trialsmentioning

confidence: 99%

Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go

Xiao-ya¹,

Zhang²,

Xie³

et al. 2019

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects at least 150 million people chronically worldwide. It is a major risk factor for cirrhosis, hepatocellular carcinoma, and death. Direct-acting antiviral therapy is very efficacious in treating HCV infection but it is inaccessible and unavailable in some developing countries. Therefore, searching for more effective and easily accessible regimens remains an urgent need. The aim of this article is to review the anti-HCV effects of herbal medicines from experimental to clinical evidence, and discuss current issues, hurdles and future perspectives for their application from bench to bedside. Numerous in vitro studies have indicated that many herbs work effectively in exerting anti-HCV activities. Yet, only a few animal experiments have been conducted that demonstrate the anti-HCV effects of these medicines; in addition, these results do not show an ability to eliminate the virus completely from the infected animals. Thus far, clinical trials have produced inconclusive anti-HCV results in terms of efficacy and safety, presumably due to the lack of the quality of methodologies used in the trials. In conclusion, despite apparent anti-HCV activities in vitro, clinical efficacy and safety of herbal medicines for the treatment of HCV infection have not been revealed convincingly. More animal studies using ideal models and more well-designed clinical trials with a larger sample sizes and longer treatment periods, taking the body habitus into consideration, are required to further assess the efficacy and safety of herbal medicines for HCV infection.

show abstract

“…Mounting evidence shows positive effects of Chinese herbal drugs as primary or adjuvant treatment in human diseases. To exemplify, in chronic viral hepatitis C, antiviral treatment is associated to partial response and several adverse effects (Duncea and Pepene, 2008); nonetheless, randomized clinical trials reported improved virological response after interferon plus Chinese herbs compared to interferon alone (Zhao et al, 2011). In traditional Chinese medicine (TCM), osteoporosis is considered to be a disorder caused by the insufficiency of kidney yang; thus, herbs such as Fructus Ligustri Lucidi (Nv-Zhen-Zi), Hominis Placenta (Zi-Hec-Che), Herba Epimedii (Yin-Yang-Huo) and Rhizoma Drynariae (Gu-Sui-Bu), thought to invigorate the kidney yang, have been used for more than 1000 years for the therapy of osteoporosis (Ma et al, 2011b;Zhang et al, 2010b).…”

Section: Introductionmentioning

confidence: 99%

Asian plants as a promising alternative to classic drugs in postmenopausal osteoporosis: A review of literature from clinical perspective

Ilie¹,

Ilie²,

Mocan³

2012

J. Med. Plants Res.

View full text Add to dashboard Cite

Osteoporosis is characterised by low bone mineral density (BMD) resulting in fragile bones with increased risk of fracture. According to statistics, 75 million people worldwide suffer from osteoporosis. However, the higher consumption of soy by the Asian population is thought to be one of the contributing factors for the lower incidence of osteoporosis-related fractures in the region. Various side effects were reported to be associated with the use of both estrogen or hormone replacement therapy, and other classical anti-fracture agents. Therefore, alternative approaches, and especially natural therapies to treat osteoporosis are currently under research. In traditional Chinese medicine, osteoporosis is considered to be a disorder caused by the insufficiency of kidney yang, and the herbs perceived to be able to tonify the kidney yang have been used for more than 1000 years as therapy. Within this context, we have systematically researched the specialty literature on the topic, in an attempt to check whether various Asian plants could constitute valid therapies in the prophylaxis and treatment of osteoporosis, especially postmenopausal one. The current evidence suggests that isoflavones as well as other compounds from Asian plants extracts may regulate bone turnover by complex mechanisms and increase BMD, thus, potentially, reducing the fracture rate.

show abstract

Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: A meta-analysis of randomised trials

Cited by 15 publications

References 19 publications

Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B

Peginterferon and Chinese herbs exert a combinatorial effect in HBeAg-positive chronic hepatitis B

Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go

Asian plants as a promising alternative to classic drugs in postmenopausal osteoporosis: A review of literature from clinical perspective

Contact Info

Product

Resources

About